| Training group (n = 60) | Validation group (n = 32) | p value |
---|---|---|---|
Gender | |||
Male | 49 | 24 | 0.993 |
Female | 11 | 8 | Â |
Age (years) | 60.60 ± 9.33 | 62.50 ± 5.86 | 0.340 |
Serum CA125 (Elevated) | 6 | 1 | 0.300 |
Serum CA199 (Elevated) | 8 | 5 | 0.241 |
Serum CEA (Elevated) | 18 | 9 | 0.112 |
Serum albumin (Reduced) | 29 | 1 | 0.315 |
Borrmann typing | |||
I–II | 32 | 10 | 0.010* |
III–IV | 28 | 22 |  |
Tumor thickness (cm) | Â | Â | Â |
 | 18.19 ± 5.75 | 15.39 ± 5.14 | 0.036* |
Degree of differentiation | |||
Low | 25 | 20 | 0.087 |
Middle-high | 35 | 12 | Â |
T-staging before NAC | |||
4 | 31 | 21 | 0.122 |
2–3 | 29 | 11 |  |
N-staging before NAC | |||
0–1 | 38 | 17 | 0.578 |
2–3 | 22 | 15 |  |
TRG | |||
0 | 19 | 4 | 0.218 |
1 | 12 | 10 | Â |
2 | 15 | 9 | Â |
3 | 14 | 9 | Â |